- Analyst Ratings
- 17-04-2025
Laidlaw Maintains Buy Rating on Aldeyra, Confident in Growth Despite FDA Shock
Shares of Aldeyra Therapeutics (NASDAQ: ALDX), a $107 million market cap biotech company, continued to be unde...
- Earnings
- 17-04-2025
Biotest shares rise after FDA approval, sales rise 6% in 2024
Biotest AG (ETR: BIOG_p) reported a 6% increase in revenue in fiscal 2024 to €726.2 million, driven by strong ...